Assessment of the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Ovarian Squamous Cell Carcinoma
- Interventions
- Drug: MK-3475 (pembrolizumab)
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT05737199
- Locations
- π―π΅
Niigata University Medical & Dental Hosptal, Niigata, Japan
SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT02840708
- Locations
- π―π΅
Niigata University Med & Dental Hospital, Niigata, Japan
Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan
Phase 2
Completed
- Conditions
- Pulmonary Alveolar Proteinosis, Autoimmune
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2019-02-07
- Lead Sponsor
- Niigata University Medical & Dental Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT02835742
- Locations
- π―π΅
Niigata University Med & Dental Hospital, Niigata, Japan
Β© Copyright 2025. All Rights Reserved by MedPath